Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage biopharmaceutical company that entered the public markets in 2019 through a business combination with Health Sciences Acquisitions Corporation 2, a SPAC sponsored by Health Sciences Holdings. The company focuses on developing treatments for autoimmune and inflammatory diseases, with its lead program centered on FcRn inhibition. As of the August 2023 8-K filing under accession number 0001764013-23-000097, Immunovant remains an active publicly traded entity in the healthcare and life sciences sector. To access full SPAC transaction history, filing timelines, and post-merger performance data on Immunovant and thousands of other deals, sign up for SpacDesk at spacdesk.com.